BioCentury
ARTICLE | Emerging Company Profile

Knopp, VCs launch Areteia with $350M series A to advance asthma candidate

Start-up co-founded by Population Health Partners and backed by Bain has Phase III-ready oral candidate that could compete with biologics

July 13, 2022 12:00 AM UTC

Newly launched spinout Areteia has drawn a series A round of up to $350 million to advance a repurposed candidate through Phase III testing for eosinophilic asthma, positioning it as an oral alternative to targeted biologics such as IL-5 inhibitors.

Bain Capital Life Sciences led the round for Areteia Therapeutics Inc., created by Knopp Biosciences LLC and Population Health Partners and launched Tuesday...

BCIQ Company Profiles

Areteia Therapeutics Inc.